- Home
- ELVA vs PLX Comparison
ELVA vs PLX Comparison
Compare ELVA & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELVA
- PLX
- Stock Information
- Founded
- ELVA 1996
- PLX 1993
- Country
- ELVA Canada
- PLX United States
- Employees
- ELVA N/A
- PLX N/A
- Industry
- ELVA
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ELVA
- PLX Health Care
- Exchange
- ELVA Nasdaq
- PLX Nasdaq
- Market Cap
- ELVA 125.5M
- PLX 122.6M
- IPO Year
- ELVA N/A
- PLX 1998
- Fundamental
- Price
- ELVA $3.79
- PLX $1.45
- Analyst Decision
- ELVA Strong Buy
- PLX Strong Buy
- Analyst Count
- ELVA 5
- PLX 1
- Target Price
- ELVA $6.10
- PLX $15.00
- AVG Volume (30 Days)
- ELVA 77.3K
- PLX 1.3M
- Earning Date
- ELVA 08-12-2025
- PLX 08-13-2025
- Dividend Yield
- ELVA N/A
- PLX N/A
- EPS Growth
- ELVA N/A
- PLX N/A
- EPS
- ELVA N/A
- PLX 0.05
- Revenue
- ELVA $48,016,000.00
- PLX $59,764,000.00
- Revenue This Year
- ELVA $55.29
- PLX $65.02
- Revenue Next Year
- ELVA $63.69
- PLX $57.34
- P/E Ratio
- ELVA N/A
- PLX $29.38
- Revenue Growth
- ELVA N/A
- PLX 0.18
- 52 Week Low
- ELVA $1.67
- PLX $0.82
- 52 Week High
- ELVA $3.89
- PLX $3.10
- Technical
- Relative Strength Index (RSI)
- ELVA 67.50
- PLX 41.06
- Support Level
- ELVA $3.11
- PLX $1.43
- Resistance Level
- ELVA $3.89
- PLX $1.54
- Average True Range (ATR)
- ELVA 0.19
- PLX 0.11
- MACD
- ELVA 0.04
- PLX 0.02
- Stochastic Oscillator
- ELVA 94.23
- PLX 28.57
About ELVA Electrovaya Inc.
Electrovaya Inc designs develop and manufacture proprietary lithium-ion batteries, battery systems, and battery-related products for energy storage, clean electric transportation and other specialized applications. It is a technology-focused company with extensive IP. The company generates revenue from the sale of batteries and battery systems. Business operations are segmented based on large format batteries and others. This technology offers enhanced safety and battery longevity. Geographically it earns key revenue from the United States.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.